Supernus Pharmaceuticals, Inc.
NYSE/NASDAQ:SUPNPharmaRockville, Maryland, United States · Est. 2005 · 200 employees
Supernus Pharmaceuticals is a specialty pharmaceutical company focused on developing and commercializing products for central nervous system disorders.
4
Pipeline Programs↗
Distinct drugs in development (Preclinical–Phase 3)
12
Indications↗
Distinct diseases across all programs
69
Clinical Trials↗
All sponsored trials (all statuses)
6
Orange Book Patents
Across 1 drug with upcoming expirations
Pipeline
Pipeline Snapshot
By Phase
4 drugs in development
Approved1
Phase 23
Preclinical1
By Therapeutic Area
top 2
Neurology
360%
Psychiatry
120%
R&D Momentum
40/100
Pipeline Velocity
11/100
Trial Completion Rate
88/100
Pipeline Concentration
44/100
Pipeline Freshness
39/100
Strategic Signals
- ↗Early-stage heavy pipeline may seek late-stage partners
- ↗Active in Psychiatry but thin pipeline — potential licensing opportunity
Activity
Key Events
Jun 18, 20268-KSUPERNUS PHARMACEUTICALS, INC. (SUPN) (CIK 0001356576)
Jan 19, 2026TrialDouble-blind, Placebo-controlled Study in Adults With Major Depressive Disorder
Jul 30, 2025TrialSPN-817 Open-Label Extension Study in Adults With Focal Onset Seizures
Dec 30, 2024TrialRENAISSANCE 2: SPN-817 Phase 2, Double-Blind, Placebo-Controlled Study in Adults with Focal Onset Seizures
Mar 25, 2024TrialOpen-label Safety and Efficacy of SPN-812 (Viloxazine Extended-release Capsule) in Adults With ADHD and Mood Symptoms
Mar 19, 2024TrialEvaluation of SPN-812 (Viloxazine Extended-release Capsule) in Preschool-age Children With ADHD
May 23, 2023TrialEvaluation of Viloxazine and Its Metabolite 5-Hydroxy-viloxazine Glucuronide Into Breast Milk in Healthy Lactating Women
May 10, 2023TrialAn Open-Label Study Evaluating Brexanolone in Adults With Tinnitus
4 more events
Feb 7, 2023TrialSafety and Tolerability Study of SPN-817 in Adult Patients With Treatment Resistant Epilepsy
Dec 14, 2022TrialA Study to Evaluate the Safety and Tolerability of SAGE-718 in Participants With Huntington's Disease
Nov 29, 2022TrialA Study to Evaluate the Effects of SAGE-718 in Participants With Mild Cognitive Impairment or Mild Dementia Due to Alzheimer's Disease (AD)
Jun 6, 2022TrialA Study to Evaluate the Effects of SAGE-718 in Participants With Parkinson's Disease Cognitive Impairment
Details
Company Info
Company Overview
$700.0M
Mkt Cap
$302.2M
Revenue
$75.1M
Cash
CEOJack Khattar
Founded2005
Employees200
HQRockville, Maryland, United States
ExchangeNYSE/NASDAQ:SUPN
Websitesupernus.com
LinkedInCompany Page
Therapeutic Focus
NeurologyPsychiatry
Recent SEC Filings
8-KJun 18, 2026
SUPERNUS PHARMACEUTICALS, INC. (SUPN) (CIK 0001356576)
Pipeline
Drug Pipeline
Indication
Preclinical
Phase 1
Phase 2
Phase 3
Approved
Neurology
Psychiatry
Neurology
Brain Injury
KynmobiPhase 2
Parkinson Disease
KynmobiApproved
Parkinsonism
KynmobiPhase 2
Progressive Supranuclear Palsy
KynmobiPreclinical
Psychiatry
Unknown / Other
Erectile Dysfunction
KynmobiApproved
Hallucinations
KynmobiPhase 2
Sexual Dysfunction
KynmobiApproved
Sleep Disorder
KynmobiApproved
Regulatory
Regulatory Timeline
20211 event
FDAApr 2
Qelbree — QELBREE
Application NDA211964 (NDA)
20261 event
SECJun 18
SUPERNUS PHARMACEUTICALS, INC. (SUPN) (CIK 0001356576)
Accession: 001-35518
Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)